Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case
Launched by HITEC-INSTITUTE OF MEDICAL SCIENCES · Feb 3, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining two different treatments to help women with Polycystic Ovarian Syndrome (PCOS) who have not responded to a common medication called Clomiphene Citrate (CC) after six cycles of trying to induce ovulation. The study will compare the effects of letrozole alone versus a combination of letrozole and CC to see which method is more effective in helping women achieve ovulation.
Women aged 20 to 40 who have been diagnosed with PCOS and have not had success with CC may be eligible to participate. Participants will undergo regular check-ups, including transvaginal ultrasounds, to monitor the development of mature eggs and the thickness of the uterine lining. It’s important to note that women with certain conditions, like premature ovarian insufficiency or thyroid issues, will not be able to join this study. Overall, this trial aims to find better treatment options for women struggling with infertility related to PCOS.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • women of 20-40 years with a history of PCOS and resistant to CC
- Exclusion Criteria:
- • Premature ovarian insufficiency
- • Husband has oligo azoospermia
- • Hypothyroidism
- • Hyperprolactinemia
About Hitec Institute Of Medical Sciences
Hitec-Institute of Medical Sciences is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong emphasis on scientific integrity and patient safety, the institute conducts rigorous clinical trials across various therapeutic areas, aiming to bring new treatments and therapies to market. Hitec's multidisciplinary team of experts collaborates with healthcare professionals and regulatory bodies to ensure compliance with the highest standards of quality and ethics. Committed to fostering partnerships that drive medical breakthroughs, Hitec is at the forefront of transforming patient care through evidence-based solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rawalpindi, Punjab, Pakistan
Patients applied
Trial Officials
Rukhsana Shaheen Afzal, MBBS,FCPS
Principal Investigator
HITEC-Institute of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported